亚太药业(002370) - 2014 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥81,934,395.66, representing a year-on-year increase of 27.58%[6] - Net profit attributable to shareholders of the listed company was ¥5,448,526.18, up 46.82% year-on-year[6] - Net profit attributable to shareholders after deducting non-recurring gains and losses was ¥5,684,496.42, an increase of 111.77% compared to the same period last year[6] - Basic earnings per share for the reporting period were ¥0.03, reflecting a 50.00% increase year-on-year[6] - The weighted average return on net assets was 0.74%, up from 0.21% in the previous year[6] - The net profit attributable to shareholders for 2014 is expected to range from 38 million to 43 million CNY, representing a year-on-year increase of 593.41% to 684.64%[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥791,357,878.69, a decrease of 1.31% compared to the end of the previous year[6] - Net assets attributable to shareholders of the listed company increased by 3.54% to ¥734,933,257.52[6] - The total number of ordinary shareholders at the end of the reporting period was 10,194[10] - Short-term borrowings decreased by 100.00% compared to the beginning of the period, as the company repaid bank loans during the reporting period[14] Cash Flow - The company reported a net cash flow from operating activities of ¥40,421,601.21, an increase of 110.96% year-on-year[6] - Net cash flow from operating activities increased by 110.96% year-on-year, driven by higher cash receipts from sales of goods and services[14] - The net cash flow from investing activities decreased by 232.88% year-on-year, mainly due to increased cash payments for fixed and intangible asset acquisitions[14] Receivables and Prepayments - Prepayments increased by 412.28% compared to the beginning of the period, mainly due to increased advance payments for raw materials[14] - Other receivables increased by 789.93% compared to the beginning of the period, primarily due to land guarantee deposits paid for a newly established wholly-owned subsidiary[14] Tax and Expenses - The company's income tax expense increased by 1016.29% year-on-year, mainly due to profit growth during the reporting period[14] - The deferred income tax assets decreased by 75.59% compared to the beginning of the period, primarily due to the reduction in deferred tax assets from profit offsetting previous losses[14] Investments - Zhejiang Yatai Pharmaceutical Co., Ltd. reported a total investment of 1,190,160.00 yuan in Zhejiang Zhenyuan Co., Ltd. with a holding of 229,110 shares, representing 0.14% of the total shares[19] - The book value of the investment in Zhejiang Zhenyuan Co., Ltd. is 4,893,789.60 yuan, with no reported gains during the reporting period[19] Future Outlook - The company anticipates a gradual improvement in performance due to the optimization of sales systems and market channels, as well as growth in revenue from quality products[18] Construction and Projects - The construction in progress increased by 71.16% compared to the beginning of the period, mainly due to increased project and equipment costs for a new production line[14]